iCAD, Inc. an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a strategic partnership with the AdMeTech Foundation, a non-profit organization with a mission to end prostate cancer as a patient care crisis and socio-economic problem. iCAD will be joining the Industrial Liaison Board of AdMeTech’s International Prostate MRI Working Group, which fosters dialogue between leading physicians, prostate cancer advocacy groups and industry to facilitate important technological breakthroughs to provide men with more accurate diagnostics for early detection and treatment of prostate cancer. AdMeTech’s research program was recently funded by Telemedicine and Advanced Technologies Research Center of the Department of Defense through a peer review process.
iCAD Announces Partnership with AdMeTech Foundation to Facilitate Advancement of Imaging Technologies
iCAD, Inc. an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, today announces a strategic partnership with the AdMeTech Foundation, a non-profit organization with a mission to end prostate cancer as a patient care crisis and socio-economic problem. iCAD will be joining the Industrial Liaison Board of AdMeTech’s International Prostate MRI Working Group, which fosters dialogue between leading physicians, prostate cancer advocacy groups and industry to facilitate important technological breakthroughs to provide men with more accurate diagnostics for early detection and treatment of prostate cancer. AdMeTech’s research program was recently funded by Telemedicine and Advanced Technologies Research Center of the Department of Defense through a peer review process.
Prostate cancer is one of the most common major cancers in the United States and the second most lethal cancer in men. The American Cancer Society has estimated that in 2009 more than 192,280 men will be diagnosed with prostate cancer, 27,360 men will die of prostate cancer, and 1 in 6 men will be affected by this disease over their lifetime. Commonly used diagnostic tests have been shown to have high false positive rates and can cause unnecessary biopsies and treatment in many men. In addition, transrectal ultrasound, while guiding biopsies to the prostate, is not reliable for detecting prostate cancer and thus, results in blind and random diagnostic procedures, which can miss at least 20 percent of cancers.
Faina Shtern, M.D., president and chief executive officer of AdMeTech said, Prostate cancer diagnostics today can be compared to mammography 20 years ago, before there was public and private funding to support the innovative research and clinical testing of promising imaging technologies. Early detection is critical for finding a cure, saving lives and improving the quality of life for men with prostate cancer. Imaging technologies provide information on cancer location, extent and aggressiveness, which is critical for individualized patient care.